본문 바로가기

A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03)

A Multicenter Phase II Study of Modified FOLFIRINOX for First-line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q1KCI Q1
저널
Cancer Research and Treatment58(1) · pp.284 · 2026
피인용
Web of Science 4Scopus 6KCI 0
FWCI (Scopus)
7.32
JCR IF
JCR 2024 3.8
ISSN
1598-2998

저자

  1. Park, Inkeun제1저자Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
  2. Lee, Jae Lyun교신저자Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
  3. Yoon, ShinkyoUniv Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
  4. Shin, Sang JoonYonsei Univ, Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea
  5. Shin, Seong-HoonKosin Univ, Gospel Hosp, Dept Internal Med, Busan, South Korea
  6. 김정훈Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Med Oncol & Hematol, Yangsan, South Korea
  7. 박권오Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Div Med Oncol & Hematol, Yangsan, South Korea
  8. Lee, Hyo JinChungnam Natl Univ Hosp, Dept Internal Med, Daejeon, South Korea

초록

Purpose This study aimed to assess the efficacy and safety of first-line modified FOLFIRINOX in patients with advanced urachal cancer. Materials and Methods The ULTIMA trial (NCT04611724) is a single-arm, open-label, multicenter phase II study evaluating modified FOLFIRINOX (oxaliplatin 85 mg/m2 over 2 hours, irinotecan 150 mg/m2 over 1.5 hours, leucovorin 400 mg/m2 over 2 hours, and 5-fluorouracil 2,400 mg/m2 over 46 hours) plus prophylactic pegteograstim in patients with recurrent or metastatic urachal cancer every 2 weeks for up to 12 cycles, or until disease progression or unacceptable toxicity. The primary endpoint was the overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the incidence of febrile neutropenia. Results Between April 2021 and November 2023, 21 patients with advanced urachal cancer were enrolled across five cancer cent-ers. The median age was 50 years (range, 28 to 68 years), with 15 male patients. The most common metastatic site was the lung (47.6%), followed by lymph nodes (38.1%) and peritoneal seeding (33.3%). Two patients and 11 patients achieved a complete and partial response, respectively, yielding an ORR of 61.9%. The study met its primary endpoint in the first stage. With a median follow-up of 23.3 months, the median PFS was 9.3 months (95% confidence interval [CI], 6.7 to 11.9), and the median OS was 19.7 months (95% CI, 14.3 to 25.1). The treatment regimen was well tolerated, with no unexpected adverse events, and no instances of febrile neutropenia or grade 4 adverse events. Conclusion In this preliminary analysis of the ULTIMA trial, Modified FOLFIRINOX demonstrated a promising ORR and PFS in patients with advanced urachal cancer. Completing the full study is essential to confirm the potential role of this regimen in the management of advanced urachal cancer.

키워드

5-FluorouracilIrinotecanOxaliplatinUrachal cancer

식별자

Scopus EID
2-s2.0-105027412387
WoS UID
001665438200024
KCI
ART003293835